Digital health innovations
We are actively seeking proven digital innovations that improve the health of people in the region and raise the quality, efficiency, safety and cost-effectiveness of delivering healthcare.
We are particularly interested to hear about innovations in the following categories:
  • Health maintenance - supporting people in maintaining their physical and mental wellbeing,
  • Prevention - alerting patients, carers or professionals when there are signs that things aren’t going well, and an intervention can prevent crises or emergencies
  • Access - providing more convenient and cost-effective ways for patients and professionals to interact. (e.g. remote monitoring or virtual consultations).
  • Learning and education - delivering information and knowledge to patients about their health or condition, or to professionals to support their continuous professional development
  • Pathways - providing tailored information to patients, carers and professionals on services to signpost people to the most appropriate place.  Ideally, this could be enhanced with real-time information about capacity.
  • Research - using digital tools to promote involvement in research & clinical trials, to streamline the capture of informed consent, and to capture research data more efficiently and conveniently.
  • Integration - tools that enable the secure, appropriate sharing of information between organisations (e.g. GPs and hospital clinicians) and sectors (e.g. NHS and Social Services) to allow patients to receive seamless care.
  • Data Visualisation - innovative ways of presenting information in a meaningful way to enable more informed decisions by patients and professionals.  This may involve aggregating data from different sources, reporting tools or graphic visualisations such as heat maps.

Ideas (Wealth creation)

Innovation 'Elevator Pitch':
Detection of acute, chronic and very early stage diseases in real time based on tests results and alerting all authorized parties about detected problems with of the essential patient information on mobiles, tablets and computers.
Overview of Innovation:
As it could be integrated and is constantly receiving data from current lab and EHR systems, it immediately detects problems in lab test results and informs doctors about new lab data received and issues detected for a particular patient. It gives access to historical data with some valuable statistical calculated and visualised data which helps doctors to understand acute, chronic, hidden or early stage health problems over secure web/mobile/tablet applications, so doctors can see these results for making better and correct decisions any time and in any location they are in at any moment.
 
Core applications of the solution are:
1. Speeding up doctors’ workflow in hospitals. At the moment, doctors in NHS have to go to rooms where there are computers with access to lab data. Quite often, doctors spend time waiting for each other to get access to their patient blood test data.

An essential part of the solution is the mobile/tablet application which can be installed on any mobile operation system iOS/Android. Which lead to:
  • Freeing up to 2 hours of doctors’ time daily
  • Increasing patient turnaround time on average by 25%
  • Increasing time reaction on most critical acute cases up to 99% 
2. In Doctors’ practice, there have been cases when a delay in days, hours or minutes in getting lab data in time is crucial for a patient’s life.  

Platform is constantly tracking blood data from the lab system, it analyzes it and alerts about critical changes in lab tests metrics and it immediately sends notifications to related parties to pay attention on a particular case.

At the moment, it tracks more than 25+ diseases and all other blood test parameters and (early and acute): AKI + CKD (all types), Sepsis and much more.

3. Platform provides historical analysis tools for blood results and gives some related insight information for each particular test parameter, so it is quick and easy to see the problem and identify potential problems at a very early stage and apply preventive actions to avoid problems. 

4. Platform has a recommendation system which seeks potential hidden problems in results. If those potential hidden problems are found, the platform gives an explanation and list of additional tests required to confirm potential problems.

5. For management team it provides deep business insight (visulised with over the time progression) of a difference scale: Hospital, Groups of Hospitals and National level about detected problems, about performance of laboratories, doctors and etc.
Stage of Development:
Close to market - Prototype near completion and final form may require additional validation/evaluation and all CE marking and regulatory requirements are in place
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Wellness and prevention of illness / Wealth creation / Digital health / Innovation and adoption / Patient and medicines safety / Person centred care
Benefit to NHS:
Potential impact of the Pin.Health on NHS
 
Product results in efficient improvements:
—  Increases time reaction on most critical acute cases up to 99%, that decreases the amount of fatal cases in hospitals
—  It frees up to 25% of doctors and GP’s time daily
—  Increases patient turnaround on average by 25%
—  Saves money on unnecessary blood tests and use of hospital beds

Product results in cost improvements:
—  It saves more than £18,000.00 GBP per doctor per annum
—  Decreases amount of unnecessary admissions up to 25%
—  Increases revenue up to 20% with the same medical headcount for commercial healthcare companies
—  Decreases the amount of unnecessary sales and blood test results in labs
—  Significant healthcare budget decrease on investment in huge IT project
 
Product results in patient care improvements:
—  Increases time reaction on most critical acute cases up to 99% that decreases the amount of fatal cases in hospitals
—  Early stage disease identification with more than 95%+ accuracy rate, and it keeps growing. It prevents serious illness conditions — move focus to preventative medicine
—  Decreases amount of fatal cases at the Hospital
—  Decreases number of doctors’ errors or human factors
 
Pin.Health supports the HSCIC Strategy (NHS Digital) 2015–2020 Strategy as well as some general European Union Strategies in Healthcare.
  1. Ensuring that every citizen’s data is protected
    Platform follows HIPAA, GDPR and UK Law in relation to data access and protection. 
  2. Establishing shared architecture and standards so everyone benefits
    Platform has API based on industry-standard protocol FHIR HL7 (JSON based protocol). Any trusted (pre-authorized by NHS) 3rd party applications and systems can connect to Pin.Health over a secure connection over API and get access to data it has, and results it has produced. 
  3. Implementing services that meet national and local needs
    As platform provides access to data and results it produced over API — any external trusted applications/systems can be built on top of it to solve other problems.
  4. Making better use of health and care information
    Pin.Health solves numerous problems which helps improve workflow in hospitals, speed up process of disease identification to save patients’ lifes and to avoid critical conditions, moving the focus to preventive medicine, proceed researches based on data platform aggregates. All of it implements better use of health and care information.
Initial Review Rating
4.20 (1 ratings)
Benefit to WM population:
In some doctors’ practices, there have been cases when a delay in days, hours, or even minutes in getting lab data in time is crucial to a patient’s life. Our platform solves this such challenges.

The platform is monitoring data from 3 perspectives — first it’s trying to detect acute diseases, after it recognizes chronic conditions and early stage conditions for each newly received test.
 
At the moment, we are tracking more than 25 diseases such as Acute Kidney Injury and Chronic Kidney diseases of all types, Anaemia of all types, Liver Disease and others, as well as all test parameters, whether they are out of range or not, and if they are at a chronic stage or an early stage.
 
One example is the AKI (Acute Kidney Injury) which is one of the diseases that is tracking in our system. AKI is a sudden and recent reduction in a person’s kidney function.  Despite the high incidence, AKI in hospitalized patients is characterized by a high rate of missed diagnosis. The missed diagnosis rate is about 57% even in high-income countries. In the UK, 1 in 5 emergency admissions into the hospital are associated with AKI, with up to 100,000 deaths each year in hospitals associated with acute kidney injury. From official UK NHS statistics, up to 30% could be prevented with the right care.

All in all platform leads to NHS operational, financial improvements as well as in longer and stronger health of the West Midlands population.
Current and planned activity: 
We would be interested in running the pilot project with one of the NHS Trust or Hospital for a period of 2-4 months. Afterwards, integration will be completed. To gather statistic about platform performance and getting first feedback from clinical environment, which leads to futher platform improvements and scaling benefits which platform gives over other NHS Trusts.
What is the intellectual property status of your innovation?:
Company is IP holder of the solution.
Return on Investment (£ Value): 
high
Return on Investment (Timescale): 
6-12 mon
Ease of scalability: 
Simple
Read more
Hide details
Anonymous 05/12/2018 - 00:09 Publish 3 comments
0
0
Votes
-99999
Innovation 'Elevator Pitch':
Clinical decision making improved via proactive digital remote monitoring. Together driving cost efficiencies, improving patient outcomes & avoiding hospital admissions. (CE Class 1a: data server sits within HSNC:  proven ¯ 67% admissions: scalable)
Overview of Innovation:
CliniTouch Vie is a digital health solution that reduces unnecessary hospital admissions.
 
CliniTouch Vie is a locked-down tablet with integrated 3G for intensive monitoring, education & empowerment with integrated direct messaging & video support.  Dynamic care plans & evidence-based algorithms enable automatic triage for healthcare teams.  Fast & simple to implement for the most at-risk patients. 
 
Launched in 2016, system is CE marked & MHRA approved. An evidence based digital health platform that clinically supports patients to better manage their condition. It has the flexibility to be adapted for data analytics & clinical decision-making support in chronic disease management (eg COPD, heart failure & diabetes), frailty & assisted discharge programmes for ambulant & non-ambulant patients
 
Clinical & economic evidence has been generated from trials with 300 respiratory patients [Ghosh et al, 2016, https://doi.org/10.12968/bjhc.2016.22.3.123]. Our evidence based digital solution increases patient access to care & promotes greater clinician-patient collaboration for the 15million people with LTCs. It drives timely, proactive intervention, minimising need for more acute costly care enabling sustainable long-term outcomes success
 
USPs:
Evidence based: Study published in the British Journal of HC Management showed 67% reduction in unscheduled COPD admissions & saving of £2,278 per patient pa. (NB: programme continues to deliver same level of savings)
 
Patient-centred: Personalisation of goals, metrics & parameters makes system truly patient centred providing real-time remote monitoring closer to home to improve patient experience & outcomes whilst generating savings
 
Secure & integrated: Data server sits within HSNC enabling it to push-pull data securely between healthcare provider & service users. Includes bespoke integrated secure video-conferencing platform with end-to-end encryption, allowing remote monitoring of medical conditions, improving quality of life & avoiding unnecessary admissions
 
Flexible Modular Architecture: Enables clinically validated question sets re: symptoms, to be easily tailored to specific therapy areas for qualitative data collection
 
Tiered Service: no upfront costs to NHS on PAYG basis:
- Digital platform integrated into existing healthcare pathways
- Light touch triage service informing local health teams of urgent priority patients for interventions
- Fully-Managed digital platform and nurse-led service providing triage & interventions
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Wellness and prevention of illness / Wealth creation / Digital health / Innovation and adoption / Patient and medicines safety / Person centred care
Benefit to NHS:
CliniTouch Vie has proven benefits and can be scaled up easily across the wider regions:
  • improved patient outcomes:
  • 67% reduction in COPD emergency admissions;
  • 13% improvement in CAT score
  • 97% of patients using CliniTouch Vie will further reduce distress and discomfort from conditions exacerbations
These were supported by:
  • improved access to healthcare: 24/7 access to healthcare, average 110 interventions per patient per annum (500% increase)
  • targeted and personalised health interventions: 7,250 personalised clinical interventions (data from 66 patients over 12 months)
  • data analytics: real-time clinical dashboards for clinical teams to prioritise patient needs; prioritised only 38% of patient clinical recordings required intervention within a 24-hour period
 

 
Patients are educated and supported to interpret the data to gain an improved understanding of their health status.CliniTouch Vie:
  1. Educates patients: supporting people to make health life choices through improving the understanding of their disease and self-management skills
  2. Enhances care for patients with chronic conditions: informing and engaging patients as part of NHS prevention agenda and creating a patient-provider collaboration
  3. Provides data analytics: making more targeted and personalised health interventions, by using disease specific algorithms to differentiate when one patient’s history or recent environmental exposures indicates a higher likelihood of flare up than another
  4. Improves patient safety: providing real time clinical and well-being data to identify early warning signs of health deterioration, medication adherence and self-management education
  5. Reduces hospital activity: providing real time management of high risk patients to prevent admissions
  6. Supports early discharge: providing hospital level diagnostics and monitoring in the home, enabling early discharge and can be used for remote clinical support post-surgery or in care-home settings
  7. Delivers workload efficiencies: supporting better patient self-management, reducing need for direct interventions and enabling staff to focus on priority patient care
  8. Offers locality wide cost savings: reduced demand leads to reduced NHS activity
 
Initial Review Rating
5.00 (2 ratings)
Benefit to WM population:
The West Midlands priorities that CliniTouch Vie can address are:
  • P2: Long Term Conditions: whole system, person centred approach
  • P4: Wellness, healthy aging and prevention of illness
  • P8: Digital Health
 
Our vision is for CliniTouch Vie to contribute towards and support the West Midlands wider vision to develop a worldwide reputation for delivering healthcare through digital technologies, proven to deliver sustainable improved outcomes and create wealth.  We have already demonstrated that it can deliver on all fronts with high risk COPD patients and is being adopted for Heart Failure, Diabetes, Cancer and Frailty pathways.  With an ageing population, often with co-morbidities, it can be used to support a more patient-centric approach to health care services in the region.
 
CliniTouch Vie supports health and wealth benefits as is a flexible, real-time remote monitoring solution, facilitating earlier discharge, prevent readmissions, reduce risk of future exacerbations and improve self-management through our inbuilt education resources.  CliniTouch Vie delivers a proactive approach to tackling symptoms, preventing exacerbations and slowing health deterioration, resulting in reduced NHS costs.  The system has an extensive data collection of medical, lifestyle, biometric and daily activity.
 
Targeting patients who are at risk or have multiple hospital admissions could significantly reduce the NHS costs to the region as well as freeing up clinic and nurse time to manage a wider caseload more efficiently. With a more collaborative, integrated, patient centred approach, utilising proven remote digital health, the West Midlands could see a potential reduction in admissions by 60%+.
 
CliniTouch Vie is a locked-down tablet, with integrated 3G for intensive monitoring, education and empowerment with integrated direct messaging and video support.  Our dynamic care plans and evidence-based algorithms enable automatic triage for healthcare teams. 
 
The tablet comes in an easy to carry case with the peripherals and can be handed to the patient at home, in clinic or upon discharge and is linked directly to the clinician web-based management portal.  Data within CliniTouch Vie tablet is stored securely within the cloud and hosted on the N3.  This makes CliniTouch Vie easy to scale due to its low technology and estates requirement, whilst delivering a high quality clinical service.
Current and planned activity: 
Current:
Spirit Digital is part of Spirit Health Group and can provide one of the most comprehensive range of solutions to support patients of all ages, IT capabilities & levels of disease severity across a wide range of conditions e.g. respiratory, cardiovascular, diabetes, cancer, frailty.
 
Spirit is establishing research collaborations with academic institutions around evidence generation for AI and machine learning. This includes collaboration on a bid to the European Space Agency to further develop the technology using satellite data.

Planned:
Spirit Digital seeks WMAHSN support ta assist with introductions and marketing of CliniTouch Vie to local CCGs. 
 
Our planned NHS engagement activity programme for the next 12 months will be through a variety of channels:
  • Direct engagement with CCGs and community Trusts
  • Application to Digital Accelerator programme
  • Case study development & sharing
  • Presentations at national conferences
  • Creating user (clinicians & patients) video footage to share with CCGs
What is the intellectual property status of your innovation?:
We hold the IP for the technology and digital health algorithms.  We collaborate with Midlands based businesses, healthcare providers and universities and retain all IP for products and services.
Return on Investment (£ Value): 
high
Return on Investment (Timescale): 
6-12 mon
Ease of scalability: 
2
Read more
Hide details
Emma-Jane Roberts 21/06/2018 - 12:25 Publish Login or Register to post comments
5
1
Votes
-99999
Innovation 'Elevator Pitch':
Currently, a GP refers Obstructive Sleep Apnoea patients to an NHS Specialised Sleep Centre. Averaging 24 wks & 3-5 hospital visits before the Patient starts treatment.
Now, a GP with SOMNOtouch can receive results in 48-72Hours (3days vs. 6Mths)
Overview of Innovation:
Currently
The vast majority of patients with Obstructive Sleep Apnoea (OSA) are referred by their GP to a Specialised Sleep Centre at an NHS Hospital with a Average waiting time 12 Weeks


Patients are initially seen by a Consultant or a Sleep Physiologist who would prescribe a Diagnostic Study to be performed either in hospital or at the patient’s home. Average waiting time 12 Weeks
The patient returns to have the sleep study done or to collect the monitor and then returns the device the next day. After a further waiting time of upto 6 Weeks the patient visits the hospital again to obtain the results of the sleep study and if Positive, to discuss treatment.
A letter is sent to the GP informing them of the results and if agreed, a prescription is issued by the GP for the recommended therapy this may also take an average of 6 Weeks to arrive.
 This is prior to any treatment being administered such as a CPAP where if used they attend annually to check on compliance and progress.
 
This 6 month process is dramatically reduced by the S-Med Service to just a few days before an intervention can be delivered.


Now
The GP fits SOMNOtouch, a Combined OSA/Hypertension Monitoring Device to the patient, after 24 hours they return to the GP practice where the device is removed and the GP uploads the data from the device to a secure NHS Digital Cloud Server.
SOMNOtouch NIBP - Five devices in One
Video link: http://www.s-med.co.uk/Products#nav-product-86
 
S-Med Ltd’s Qualified and Registered Physiologists interprets the study and provides a recommendation for further treatment or investigation within 24 to 48 hours to the GP surgery. (All analysis and interpretations are supervised by a senior Consultant).
 
The report is sent to the GP who would then provide a prescription for the relevant therapy to be provided.
 
Thus within 48 to 72 hours a patient can be treated or directed for additional investigations or treatment before their condition deteriorates.

 
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Advanced diagnostics, genomics and precision medicine / Wellness and prevention of illness / Wealth creation / Clinical trials and evidence / Digital health / Innovation and adoption / Patient and medicines safety / Person centred care
Benefit to NHS:
Faster response times and time to providing treatment from an average time from referral to treatment of 6 months (24 weeks) down to 4 to 5 days (1 week). With the added benefit if there are more critical underlying conditions then these may be picked up and dealt with quickly
 
Reduction in costs of patients being referred to NHS sleep centres thus less calls and pressure on such specialist clinics e.g.:
 
Reimbursement Tariffs for OSA and Hypertension
Current reimbursement guidelines from the Department of Health are:
  • For Ambulatory Sleep Diagnostic Study: £391.00
  • For 24-Hour NIBP Study: £268.00 (UCL NHS Foundation Trust, there is no NHS tariff)
  • For 24-Hour ECG Study: Recording - £268.00 plus Analysis £215.00 (UCL NHS Foundation Trust, there is no NHS tariff)
 
Cost Savings Calculation
Assuming the following:
  1. Adult Population of the England is Approx. 45 million
  2. BLF figure show approx. 10% of population suffers from OSA = 4.5 million
  3. DH figures show that approx. 30% of adult population has Hypertension = 13.5 million
  4. Public Health England shows that 1.3 million people have Atrial Fibrillation
 
The cost of referring 1% of the above population to hospital annually, will cost approximately:
  1. OSA – 45,000 £32 million per year.
  2. Hypertension – 135,000 £79 million per year
  3. AF – 13,000 £10.5 million per year
 
Total cost of £121.5 million
Cost of S-Med Service - £38.6 million
Savings to NHS = £83 million per year.
 
Aside from OSA, this equipment can be used for chronic heart conditions studies as well as more longitudinal studies adding a wealth of data for clinicians to inform them of patient’s conditions at work, rest and play without the equipment being intrusive and disturbing as current cuff based systems thereby removing the abnormal results they can provide. Thus, this equipment may also be of benefit to clinical trial units or during treatment to monitor the physiological effects experienced by patients undergoing a drug or other clinical interventions. 
Initial Review Rating
5.00 (1 ratings)
Benefit to WM population:
In addition to patients getting a faster diagnosis, it will reduce the burdens on NHS Trusts not only from the reduction on 1st line referrals to hospitals, but from patients conditions deteriorating, or suffering economic or social problems waiting 6 months for a diagnosis and treatment to be considered.

North West Innovation Agency (AHSN) will be conducting a pilot which will monitor 75 patients via a number of GP’s Practices. Results should be available by the End of February 2018.
As a West Midlands based company we would welcome an opportunity to work with NHS Trusts and CCG’s within the region to help us grow this service within the UK for the NHS and to increase our team to service and facilitate such requirements.  
Current and planned activity: 
Current NHS engagement
  • Embarking on a NIA application with North West Innovation Agency
  • Submitted an application into the ITP based on experience and adoption within the NWIA area.
  • Considering a NIHR project following a meeting at AHSN meeting - Speaking with West Midlands NIHR/CRN
Requested NHS engagement
  • Procurement / Adoption of: -  Would welcome assistance to gain greater Adoption by Trusts and CCGs within the West Midlands
     
  • Evaluation / Validation / Clinical Trial – Interested in trials for use of our ambulatory equipment (SOMNOtouch) within new clinical areas to show its versatility and extend its clinical use to provide validated evidence within in these new areas.
     
  • Project Assistance S-Med is interested in locating potential clinical / academic collaborators to engage in their current work and to explore other clinical applications of their technology.
What is the intellectual property status of your innovation?:
Device IP held by SOMNOmedics Germany. Clinical diagnostic and reporting service is owned by S-Med Ltd.
Reg. CE0494
We have obtained IGSoC Level 2 (ODS Code: 8JP12)
Return on Investment (£ Value): 
high
Return on Investment (Timescale): 
2 years
Ease of scalability: 
3
Read more
Hide details
Selwyn Sher 03/10/2017 - 13:27 Publish Login or Register to post comments
0
0
Votes
-99999
Innovation 'Elevator Pitch':
eCAS Card simplifies recording activity data at point of care in busy A&E Departs.  This data is available to all clinical staff with associated patient safety checks. Patient record is more complete accurately reflecting activity & improving coding
Overview of Innovation:
Paperlite - The eCAS Card system is a replacement for the paper Casualty Card used in an Accident & Emergency Department and focuses on simplifying activity recording so the patient record contains rich clinical and nursing content. 
 
Data Collection – The eCAS Card system simplifies and streamlines data collection by reflecting the processes and work flow within A&E Departments whilst integrating with the Trust’s PAS and key IT systems to ensure administrative functions are minimised.
 
Accessibility - No longer are nurses and clinicians required to search for a single paper record as they will have access to the latest patient information anywhere within the hospital where there is browser access to the network.  The same patient record can be viewed with the capability of updating different parts of the record by multiple people simultaneously.
 
Accessible via multiple devices including Tablets, iPADs and C.O.Ws utilising NHS security protocols.
 
Monitoring - the system monitors “wait times” and provides simple, visual updates on screen to assist with meeting targets.  Utilising the data provided by nursing staff, Sepsis, VTE, Child and adult safeguarding checks are undertaken and appropriate alerts raised if the data meets certain parameters.
 
  • nursing staff report that their capacity to treat patients and record their activity increases with the use of the eCAS Card service
  • clinicians benefit from having the latest patient information to ensure appropriate and timely treatment.
  • administrative staff note a significant reduction in time spent chasing paper notes, scanning CAS Cards and completing activity data not entered prior to discharge.
 
Data Sharing – the eCAS Card service ensures accurate and complete activity recording that results in an improved patient record which is then used for;
  • automatic production and e-mailing of GP attendance letters
  • all necessary reports and correspondence
  • A&E data available for Inpatient episode where a patient is admitted
  • simplified coding
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Wealth creation / Digital health / Person centred care
Benefit to NHS:
The use of eCAS Card system improves patient care, efficiency, and improves activity reporting by:

Patient Care
  • Improved patient flow facilitates quicker turnaround
  • Ensures that the right care is delivered as the clinical staff has the most up to date information at hand
  • Sepsis Screening, VTE, Child and adult safeguarding checks removes the potential for a condition/issue to be overlooked  
  • Accurate record keeping ensures episode details can be relied upon for any follow-up treatment and as part of the patient’s medical history.
Provides Efficiency
  • Increase in productivity from nursing staff who are able to Triage and stream patients quicker.
  • Information can be accesses by the clinical staff via a mobile device reducing time locating the patient record or the correct form to complete.
  • Removes the necessity for double entry and transcription errors this can cause.
  • Reduction in administrative tasks, including scanning of paper Casualty Cards, production and postage of Attendance Letters
  • Facilitates direct communication and documentation with patients GP’s
  • Interfaces with PAS and Ambulance information systems for seamless transfer of patients
  • Integrated with Referral Management services to allow for the Demand Management to ensure patient is treated in the most appropriate location by the optimum service
  • Key step in becoming a paper-lite NHS organisation
 
Improved Data Quality
  • Improved recording of activity to allow for more accurate charging and ensuring the Trust is paid for all its activity and improves CQUIN Reporting
  • Outputs audit data for department requirements and allows for the management of A&E Services based on accurate, up-to-the-minute information.
  • Integration with Primary Care to share patient data
  • Integration with Secondary Care to maintain Care Pathway if an attendance leads to an admission
Initial Review Rating
5.00 (1 ratings)
Benefit to WM population:
Patient Benefits
  • Improved patient experiences at A&E
  • Streamlined and efficient patient triage & treatment delivery via clear trust pathways reducing time in department
  • Consistent level of service and treatment
  • Safeguarding and inbuilt alerts for Sepsis and VTE ensures important checks are not missed
  • Reduced anxiety as clinical and nursing staff do not need to ask the same question multiple times
  • Greater confidence in the service as professionals have the information they require
  • Improved communication allows for seamless follow-up care if required
 
Trust Benefits
  • Most efficient use of resources including physical locations, equipment, staff, patient information etc.
  • Improved data collection for each episode ensures patient data is both complete and accurate, increasing confidence in nursing care and clinical decisions
  • Activity accurately recorded improving CQUIN reporting and ensuring all attendances are correctly charged
  • Clear management and audit data to allow for proactive management of the A&E Department and assessment of process efficiency.
 
Regional Benefits
  • Opportunities to manage demand of urgent care services by sharing load across Healthcare Economy as part of Sustainability & Transformation Plan.
  • Significant Patient Safety benefits by being able to consistently monitor and review vulnerable children and adults across the region.
Current and planned activity: 
Current Activity
eCAS Card used successfully by East Kent Hospital University NHS Foundation Trust since 2015.

WASP has developed additional innovative products and services for other NHS Trusts, inc. London North West Healthcare & Northampton General Hospital NHS Trusts.

WASP is undertaking  Marketing Campaign to raise awareness of products and services that support improved operational efficiency of trusts, but which can be tailored to meet the demands of STPs & Local Digital Roadmaps.

Planned Activity
  • Promotion - Meet with region’s senior managers involved with Local Digital Roadmaps to raise awareness of WASP’s current capability & strategic ambitions.
  • Adoption - Additional adoption sites within the West Midlands for the eCAS Card service.
  • Innovation –Work with an Healthcare Economy in order to implement new technology to join up the patient, GP, OOH services, NHS 111, CCG and Acute Trust providers to co-ordinate & manage Urgent & Emergency Care services demand.
  • Resolve the issues below.
What is the intellectual property status of your innovation?:
The eCAS Card Service has been specified, developed and supported by WASP Software.  The software “Code Base” is managed by the WASP Development Team and released in compiled form through our Operations Team.
On this basis, all Intellectual Property and copyright (although not registered) resides with WASP.
Return on Investment (£ Value): 
high
Return on Investment (Timescale): 
6-12 mon
Ease of scalability: 
3
Read more
Hide details
Michael Brett 12/09/2017 - 16:37 Publish Login or Register to post comments
0
0
Votes
-99999
Innovation 'Elevator Pitch':
Our expert people and advanced health analytics reveal insights from complex data that enable health & care professionals working across the West Midlands to make better decisions for the patients and populations they serve.
Overview of Innovation:
Sollis and the world-renowned Johns Hopkins University have collaborated to produce a population health analytics platform that helps health & care professionals transform services for patients and populations.
 
Sollis Clarity and The Johns Hopkins  ACG ®System is a person-focused case-mix system that captures the multi-dimensional nature of an individual’s health. It considers the total disease experience of each patient, including the implications of co-occurring disease, encouraging a holistic view of the patient rather than the management of specific diseases or episodes.
 
Sollis Clarity supports:
  • Case Finding - Patient level risk stratification
  • Resource Management - Case-mix risk adjustment and benchmarking
  • Population Health Needs Assessment - Population level risk stratification
  • Fair Shares Budgeting - Capitated budget setting
 
Sollis Clarity delivers robust business analytics and data management to identify and analyse populations across the continuum of care to help health & care providers and commissioners get a precise understanding of patterns of mult-morbidity across populations and its relationship to utilisation, costs and outcomes.
 
Sollis Clarity delivers insights into the morbidity patterns of different populations, supporting population health management, service transformation, integrated care and, ultimately, better outcomes for patients.
 
Sollis Clarity goes beyond patient level risk stratification. Risk stratification at a population level helps the health economy — providers and commissioners — analyse and minimise the progression of diseases and the exacerbation of co-morbidities. When combined with the ACG System it is a comprehensive family of measurement tools designed to help explain and predict how healthcare resources are delivered and consumed.
 
Sollis Clarity provides the evidence base to support:
  • Planning and service re-design
  • Clinical decision making
  • Outcomes-based commissioning
  • Risk stratification and predictive modelling
  • Population profiling / segmentation
  • Case-mix adjusted benchmarking
  • Integrated multi-disciplinary care
To view Sollis - Nigel's Story - click here.
To view UK Healthcare data analytics for NHS CCGs - click here.
To view The Proactive Care at Brighton & Hove - click here.
To view Population Profiling at NHS Slough CCG - click here.
To view Using Data to Gain Greater Insight - click here.
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Wealth creation / Digital health
Benefit to NHS:
Population health analytics delivers an evidence base (insights from data) that supports large scale health & care service transformation. It is an essential component of any Population Health Management strategy and as such underpins the journey to a fully fledged Accountable Care System (ACS).

The Sollis Clarity health analytics platform is a modular system with mix-and-match components to help you achieve your healthcare analysis and commissioning/budgeting requirements.
 
Population health management helps Health & Care stakeholders identify and quantify the drivers and outcomes for addressing the needs of local populations.
 
Led by directors with decades of NHS experience, Sollis analytics software and professional services have been used to analyse data on nearly half the population of England. We believe patient-centred care strategies based on the needs of local populations provide the key to better population health management.
 
Sollis Clarity is helping several CCGs in the UK to implement new reporting and service planning initiatives.  To view examples of ‘Service Transformation: Stories from the CCG Frontline’ summarising how CCGs are using the insights provided by Clarity Patients and ACG® System analysis for service planning and transformation – click here.
 
The Sollis Clarity health analytics platform has two distinct but complementary solutions — Clarity Patients and Clarity Finance — address population health management and financial analysis respectively.
 
Clarity Patients, combined with the Johns Hopkins ACG® System, provides a comprehensive family of measurement tools that helps explain how healthcare resources are delivered and consumed. It supports new commissioning models such as Commissioning for Value, Outcomes Based Commissioning and Year‑of‑Care Commissioning. It delivers analytics that provide insights to support health & care interventions and innovation and it will help you track the success — or otherwise — of those innovations over time.
 
Clarity Finance provides contract management and activity costing with multiple tariffs, giving you business critical evidence on which to base commissioning decisions. It enables you to store and compare different versions of cost and volume type tariffs as well as non-activity tariffs, such as year of care or outcome based currencies, to give you insights on the most effective commissioning decisions.
Initial Review Rating
5.00 (1 ratings)
Benefit to WM population:
Knowledge of the risk profile of the region’s population (based around a population segmentation approach) will help Health & Care stakeholders across the West Midlands commission and deliver appropriate preventative services that will drive positive health outcomes for the 'at need' populations of the West Midlands. 

Through the innovative use of information technology to identify patients most in need of an intervention (impactable patient cohorts) Sollis Clarity helps to identify patients who could most benefit from earlier, better informed health care interventions.
 
The Sollis population health analytics platform allows the patient population to be risk assessed to provide timely, evidential data to all members of a Multi-Disciplinary Team (MDT), to include clinicians but not limnited to them. This enables MDT members to provide focused levels of care to specific groups of patients, reducing the risk of a patient’s condition worsening due to it being identified early so assisting MDT members in identifying and improving the care of at-risk patients.
 
Much can be achieved through the acquisition of primary care, secondary care, community care, mental health, prescribing and social care data. It can provide a rich understanding of how healthcare resources are delivered and consumed and by whom. Such analysis can aid an understanding of whether scarce resources are being deployed to those population groups in greatest need.
 
It is important that any population health analysis should focus not on single disease conditions, but on the burden of multi-morbidity observable in a local population.  Population health programmes that have the best chance of success will be those that demonstrate an understanding of the importance of multi-morbidity and its impact on the local health and care economy.
 
Using data to identify early healthcare interventions can provide significant benefits to patients, particularly those with long-term conditions. Providing the functionality to make real time decisions based on clinical evidence will improve outcomes for patients.
 
Sollis exist to help our customers deliver better patient outcomes, better patient experiences at an affordable cost and are wholly focused on the delivery of insights that will help deliver a sustainable and transformed health and care system in the West Midlands.
Current and planned activity: 
We are currently providing analytics support to thirty (30) plus Clinical Commissioning Groups (CCGs) nationally as well as nine hundred (900) plus GP practices and a number of NHS Vanguards, principally Multispecialty Community Providers (MCPs).

We would like to engage with health and care professionals involved in the development and evaluation of New Care Models throughout the West Midlands who want to use evidence based data to understand patterns of multi-morbidity and its relationship to utilisation, costs and outcomes. We are particularly interested in engaging with Sustainability & Transformation Paernerships (STPs) and emerging Accountable Care Systems (ACS).
What is the intellectual property status of your innovation?:
Sollis owns all Intellectual Property (IP) for the following software applications:
  • Sollis Clarity (Population Analytics Platform)
  • Sollis Clarity Patients
  • Sollis Clarity Finance
 Johns Hopkins Health Care (JHHC) owns all Intellectual Property (IP) for the following software:
  • ACG® System
 Also:
  • ISO9001
  • IG Toolkit Certified
Return on Investment (£ Value): 
high
Return on Investment (Timescale): 
3 years +
Ease of scalability: 
2
Read more
Hide details
Nigel Slone 21/08/2017 - 11:53 Publish Login or Register to post comments
0
0
Votes
-99999
Innovation 'Elevator Pitch':
Alamac work in partnership with health and social care organisations / systems to help diagnose challenges in real-time, identify key actions based on objective data, and implement changes which result in sustainable improvement.
Overview of Innovation:
Alamac are specialists in behavioural change and sustainable performance improvement. We apply a simple process, using a proven clinical method, and combine this with our technology to create sustainable change.

We work with our partner organisations to understand the flow of patients through different pathways of care - including acute / hospital care, community health, primary care and social care. We work alongside teams to gather relevant, current data and act upon it.

We develop the individuals and teams to use this data as information to drive action. Teams are able to identify the 'cause and effect' of pressure points and actions are then put in place to improve the system performance, the patient's journey and quality outcomes.

Our team bring a wealth of experience in clinical practice, operations management and senior leadership. 100% of our delivery team are clinically or NHS trained leaders with the experience, skill and credibility to deliver. They bring their experience and knowledge of working with over 45 systems/organisations across the NHS and Social care. We act as a critical friend, helping teams to think differently and create a disciplined culture of real-time improvement.

We deploy a simple process based around the transparency of daily data. Through our facilitated ‘Test and Learn Cycles’, daily use of this intelligence involving senior leads from across the system allows teams to diagnose system issues in real time, and use objective information to identify actions to tackle these issues.

Our approach creates a fundamental change in the way teams work. It supports collaboration and integration across organisational boundaries. Our process allows teams to work on objective intelligence and reality, rather than emotion and myth. We create a disciplined culture of support rather than blame and of action rather than story. Our encouragement of predictions means that teams drive the changes they want to see and become less reactive. This delivers a greater grip on the issues at hand, removes uncertainty and drive proactive actions.

By following our process every day, consistently and persistently, we create lasting culture change.
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Wealth creation / Digital health / Innovation and adoption
Benefit to NHS:
  • We deliver transparency of information across all parts of the organisation/system- providing ‘One Version of the Truth’ that is used daily to form actions to deliver benefit.
  • We use daily forums to fix 'in-day' problems and to monitor systemic solution delivery. During this period we help teams to identify and collate measures, understand what targets they want to set, and begin to take earlier and better decisions to deliver incremental improvement.
  • We help teams to develop a system and a forum to share intense and constructive feedback, as well as a new numerate language to drive a culture of real-time improvement.
  • The process supports individuals, teams and organisations to hold to account based on objective information.
  • We develop and coach individuals and teams in improvement methodology to deliver sustainability to the organisations and system
The outputs are:
  • Integration of and patient pathway improvement and service reconfiguration
  • Rebalance of capacity and demand (management)
  • Stabilisation of operational performance to build recovery and resilience
  • Construction of associated programme management and governance
  • Deliver in excess of 10x ROI – 30% of which is cost saving
  • Leadership development and empowerment of front line leaders and senior and executive teams
  • True ‘clinical team to board’ transparency, reporting and assurance.
  • Trained and skilled workforce in continual improvement
Initial Review Rating
5.00 (1 ratings)
Benefit to WM population:
Through our simple process, clinical method and technology we can support the WM to deliver improved and sustained performance; integration and collaboration and a skilled workforce in improvement methodology. Some examples our outlined below:

DTOC Reduction
In a medium sized health and social care system, a key issue impacting on patient flow was identified as underutilised capacity within the community hospitals.

We developed a key set of measures to enable a better understanding of the ‘cause and the effect’ of the underutilised capacity and supported the teams in identifying and implementing appropriate actions.

The result of the approach was an increase in community bed utilisation. The effect of this was a reduction in the number of medically fit patients in the Acute Hospital.




Improving Quality
Working with the frontline teams delivering patient care, we support them to analyse their own data, take ownership of it and develop the confidence to use and make decisions based upon it. The staff and teams feel empowered to identify and implement actions that they can monitor, in real time, to ensure actions are having the intended effect.

In one ward we identified that 45% of their falls were occurring on a Sunday.

Through working with the ward to diagnose the ‘cause and effect’ of this number the ward sister adjusted her roster (at no additional cost) to ensure a dementia champion was on duty on a Sunday.

This resulted in the number of falls on a Sunday reducing to 0 which was sustained.


By impacting on quality outcomes, such as falls, there has been a cost saving associated for our clients. The average cost of a fall to an acute hospital is £3000, (The Kings Fund, 2013).

A client example:


Releasing Time to Care
In one of our clients we were able to capture key measures required for ‘Audits of Key Performance Indicator Bundles’ at the front line, and in real time, as part of the daily standard work.

Prior to this, the audits were being completed by a clinician in each team taking 1 day a month in 21 teams away from clinical care.

We enabled the staff to rapidly complete the audits as part of the daily routine releasing clinical time back to the teams. It also released time in the governance team as the manual process was no longer needed.

The clinical time saved has been costed as:
1 day/month for 21 teams = 252 days/year
Costed at midpoint Band 5 = £24,211 savings/year
Current and planned activity: 
Alamac would like the opportunity to work with healthcare providers in the West Midlands, as well as work more closely with the West Midlands Patient Safety Collaborative, hosted by the WMAHSN, that aims to improve safety and continually reduce avoidable harm by supporting organisations in working together to develop, implement, share and spread proven safety interventions that are based on rigorous, evidence-based scientific methodologies.
What is the intellectual property status of your innovation?:
Our improvement methodology - simple process, clinical method and our technology is the intellectual property of Alamac
Return on Investment (£ Value): 
high
Return on Investment (Timescale): 
1 year
Ease of scalability: 
2
Read more
Hide details
Sarah McGovern 06/07/2017 - 13:55 Publish Login or Register to post comments
6
1
Votes
-99999
Innovation 'Elevator Pitch':
Complicated and laborious document production processes become easier to manage through intelligent workflow software that remembers and organises information with built-in reporting to manage production targets.
 
Overview of Innovation:
Epro Scrik is a third generation dictation, forms and documentation management mobile technology solution, designed by clinicians.
 
The solution uses a unique combination of structured data, dictation, templating, speech recognition and usability to revolutionise clinical correspondence and document production workflows for clinicians saving time and money. 
 
Scrik then leverages these a second time to enable clinicians to access and search patient documentation and notes quickly, presenting information in the fastest, most convenient way possible.
 
Complicated and laborious document production processes become easier to manage through intelligent workflow software that remembers and organises information with built-in reporting to manage production targets.
 
The solution is fully interoperable and very flexible. It can enhance legacy EPRs and integrate with legacy PAS systems. It can be combined with Epro’s wider group of clinical functionality for clinical workflow, patient journey and document management to help NHS trusts improve patient safety, increase efficiencies and achieve a paperlight working environment.
 
 
With Epro Scrik, you can:
 
  • Create templated clinic letters with just five clicks.
 
  • Make more informed medical decisions with greater access to current and historical information
 
  • Reduce risk of clinical errors by facilitating more legible, complete and accurate information
 
  • Meet your document delivery targets through faster letter production
 
  • Make better use of staff time and skills by removing or automating repetitive tasks
 
  • Save money on paper, printing and postage
 
  • Improve coordination and correspondence with other care providers, such as GPs
 
  • Increase clinical efficiency with speedy, consistent access to patient information at the point-of-care
 
 
 
Core features:
 
  • Capture clinical information with industry leading digital dictation, speech recognition and snippet technology
 
  • Enable mobile working for clinicians
 
  • Chronological view of historical patient information
 
  • View, manage and schedule clinic appointments
 
  • Integrate with / record SNOMED coded patient allergies information
 
  • Full visibility of patient admissions, transfers and discharges
 
  • Safeguard patient information by specialty or department
 
  • Electronically distribute documents to GPs and other care providers
 
  • Powerful reporting functionality
 
Links seamlessly with patient administration systems Import ad hoc documents 
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Wealth creation / Digital health / Patient and medicines safety / Person centred care
Benefit to NHS:
Video case study: Transforming clinical correspondence performance at Taunton and Somerset
Watch the video here: youtube.com/watch?v=uCJpF86jslo
Anticipated outcomes:
 
Epro worked with Taunton & Somerset NHS Foundation Trust to transform its clinical correspondence. The trust reported improved patient experience (due to speedier communication), decreased stress among staff, faster clinical access to patient letters, reduced clinical errors, and compliance with audit and access requirements.
  • £1.1m of secretaries’ and clinicians’ time
  • £11K on administrative costs £4.3K spend on printing
  • 96% reduction in letter transcription backlog
  • 100% compliance with 7 day letter delivery CQUIN

£4.3K spend on printing
Initial Review Rating
4.60 (1 ratings)
Benefit to WM population:
We are launching a telemarketing campaign on the 6th June across the West Midlands offering a FREE of Charge Paperlight Clinic to any NHS Trust in the West Midlands.
Current and planned activity: 
We are launching a telemarketing campaign on the 6th June across the West Midlands offering a FREE of Charge Paperlight Clinic to any NHS Trust in the West Midlands.
What is the intellectual property status of your innovation?:
IP is with Epro only
Return on Investment (£ Value): 
high
Return on Investment (Timescale): 
0-6 mon
Ease of scalability: 
Simple
Read more
Hide details
Keli Shipley 04/06/2017 - 22:43 Publish Login or Register to post comments
0
0
Votes
-99999
Innovation 'Elevator Pitch':
MIRA is a software application designed to make physiotherapy fun and convenient for patients in need of rehabilitation. It turns physical exercises into video-games and uses Microsoft Kinect to track and assess patient treatment compliance.
 
Overview of Innovation:
Physiotherapy and rehabilitation can be a long, difficult and sometimes painful process. Treatment plans can be cumbersome and a slow recovery can be disempowering for patients. 70% of patients do not adhere to home exercises, which increases the total time needed for recovery, leading to higher costs for the healthcare sector.

MIRA displays these exercises as video-games and asks patients to complete the recommended movements to progress through each game level. As a result, patients are playing, while at the same time actually recovering. The patient’s performance data is also tracked, storing all the repetitions, improvements or issues for the therapists to adapt the treatment accordingly. As each patient and their treatment require careful planning, MIRA is designed as a tool for the therapists, to enable specialists to customise the treatment for each individual. Our innovative software can be tailored to the patient’s condition, needs and goals (stroke, falls prevention, MSK disorders etc.), using off-the shelf hardware (laptop/PC and motion sensor).

The software application is registered as a Class I Medical Device in Europe (CE Mark) and can be installed in any clinical environments where patients go for their regular treatment sessions, as well as at home where patients can be remotely monitored by their therapists. This allows the patient to exercises at home under the remote supervision of a healthcare provider. Furthermore, MIRA reduces costs by supplementing staff and reducing waiting times, as well as by decreasing the necessary number of clinic visits and the travel costs associated to them.

The system runs on Windows PCs, using Microsoft Kinect, a mainstream motion capture camera, to engage and track patients throughout their treatment.

MIRA Rehab has 14 UK institutions and another 44 worldwide, helping 600 patients monthly.  The youngest patient to have ever used the system was 3 years old, while the oldest is 102. MIRA was recently featured on BBC, as well as on TED.com in 2015.












www.mirarehab.com

Video links:
MIRA – Play your way to recovery
MIRA – Helping older people regain their mobility
 
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Wellness and prevention of illness / Wealth creation / Clinical trials and evidence / Digital health / Person centred care
Benefit to NHS:
The primary benefits to NHS provided by using MIRA are mostly related to health outcomes, efficiency & cost effectiveness. Thus, MIRA can:
  • Supplement staff shortage and reduce waiting times, by enabling more patients to be treated at the same time at the clinic as well as remotely supervised at home
  • Reduce recovery time for a large group of patients by increasing motivation for the adherence to treatment through an interactive and engaging exergaming tool
  • Reduce costs associated to travel by decreasing the necessary number of visits to the clinic
  • Prevent further injury or surgery and thus reduce important costs associated to further hospitalisations and treatment caused by lack of compliance to the initial treatment
 
Quotes from NHS clients
"The [MIRA] concept is that it will replace me, as the clinician, or the therapist who is going to do the exercises with the patient. Not for all of the time, but for a part of the time. So it will supplement what we do and it will also improve patient care because patients will do it better based on the principles of gamification. When I describe it to people, people just go Wow! If this continues, it will change the way modern medicine is practiced"
Mr Bibhas Roy,
Shoulder and Elbow Surgeon, Central Manchester NHS Foundation Trust 
               
“There is huge potential. I give a lot of talks to older people and they are very interested…There is a great need there. You can have a lot of patients using the exergames at home with the physio reviewing and keeping an eye. With the data that is remotely sent to the clinic you can very easily see if individuals are complying, improving, and if they are not improving whether they need a visit.
Emma Stanmore,
Lecturer in Nursing, The University of Manchester
 
“Many individuals over the age of 65 haven’t played computer games before, but those who have been helping us test the technology have given us very positive feedback.”
Emma Stanmore,
Lecturer in Nursing, The University of Manchester
 
 “MIRA is an innovative product that could alter the way therapy is delivered to patients in the future. It has the potential for patients to be more active in their rehabilitation, which should result in improved patient and service outcomes.”
Mark McGlinchey,
Clinical Specialist Physiotherapist, Guy’s & St. Thomas’ NHS Foundation Trust
Initial Review Rating
5.00 (1 ratings)
Benefit to WM population:
Benefits for WM
  • An innovative tool that offers the possibility to have a better supervision of their patients, better medical outcomes and a more competitive practice
  • Created based on the best available clinical evidence (ex. Falls prevention exercise package) and validated in clinical trials
  • Net average saving associated with the use of Exergames for falls prevention would be £1,202 per patient per year for one MIRA unit (Health Economic Report by JB Medical)
  • The clinic can offer MIRA as a separate therapy service, developing a new business opportunity, improving treatment and physiotherapy services delivery (like reducing waiting times)
  • MIRA allows them to track patients’ compliance and progress at home
  • Reduce readmission and costs associated to further treatment and hospitalisation due to non-adherence to initial prescribed therapy (ex. Home exercises are more likely to be done if patients are being checked and if they have an engaging tool.
  • Specific therapy plans for patients can be prescribed from any location, and  it offers a suit of customisable exercises and games that therapist can easily tailor as they see fit for their patients
  • Possibility to monitor and engage more patients at the same time
  • Based on this modern instrument with its data gathering feature, therapists can access new research opportunities, important movement data and statistics that were not easily available before
  • Patient data is safe – data protection and security regulations have been carefully implemented to ensure best protection and security measures required have been implemented
Benefits for its population
  • An attractive environment through gamification engages patients to perform the prescribed exercises and comply with their treatment avoiding further complications and reducing recovery time
  • A new, easy and fun way to interact with rehabilitation or therapy
  • Patients can continue exercising in between clinic sessions being guided and supervised by a medical specialist, keeping a closer contact with the clinicians
  • Based on occupational therapy MIRA distracts the patients’ suffering and focus on pain while exercising
  • Increase the quality of patients’ life and of their families
  • When they cannot attend the therapy sessions MIRA is an efficient tool and fast way to perform the prescribed treatment plans at home
Current and planned activity: 
Current NHS Engagement:
1. Central Manchester University Hospitals NHS Foundation Trust (CMFT)
2. Guy's and St. Thomas' NHS Foundation Trust (GSTT)
3. Epsom and St Helier University Hospitals NHS Trust (ESTH)
 
Planned Activities/Upcoming:
Five other NHS organisations are in the process of implementing MIRA in their treatment delivery;

MIRA is a platform created to support extensions with new packages targeting new types of rehabilitation (hand fine movements, aerobics, speech therapy, etc.). Thus, we are willing to engage with clinical partners for clinical input, studies and validation on the development of the new modules. 

(See attached NHS Engagement document for further details)
 
What is the intellectual property status of your innovation?:
No patent on product as it is a software product (trade secret). We have full copyright of the software and source code of the application.

We are in the process of registering the MIRA trademark.
Return on Investment (£ Value): 
Very high
Return on Investment (Timescale): 
1 year
Ease of scalability: 
3
Read more
Hide details
Cosmin Mihaiu 11/04/2017 - 16:53 Publish Login or Register to post comments
6
4
Votes
-99999
Innovation 'Elevator Pitch':
SMC provides an innovative, integrated, digital platform solution that deliver better patient outcomes, greater self-management and delivers healthcare more efficiently. The system is highly configurable and customisable and deployable at scale.
Overview of Innovation:
SPS have created an open, future proofed digital platform that harnesses and integrates a range of mobile, communication and wearable technologies to pre-emptively and pro-actively support improved patient outcomes while enabling more efficient healthcare service delivery across primary, secondary and social care environments.
Our mobile health (mHealth), telemedicine and telecoaching solutions use familiar mobile and ‘cloud’ based technology. It has been proven to  support service redesign and deliver more efficient, patient centric healthcare that’s cost effective, simple to use and easy to implement at scale.
Our ‘open’ architecture and web based platform enables more holistic Long Term Condition management services by leveraging a range of technologies across mobile, tablet, text, video and voice to deliver a highly flexible solution for healthcare professionals and patients. Mobile health (mHealth) enhances patient outcomes by enabling clinicians to pro-actively and pre-emptively monitor patients remotely while also enabling the individual to better understand and manage their condition that results in improved patient outcomes, reduced visits to hospital and local GP’s Surgeries.
Our SMCTM solution can be customised to meet any Long Term Condition (LTC), co-morbidity or medical condition that an individual may suffer from. It can support one or multiple LTCs, as well as any other health or mental health condition where a question or vital sign measurement can be of benefit. To date core commissioning has been focused on supporting people who suffer from Heart Failure, Coronary Heart Disease, Hypertension, Chronic Obstructive Pulmonary Disease, Asthma and Diabetes, but we have also developed profiles to support Urinary Tract Infection, Falls Prevention, Dementia and Depression management, Cystic Fibrosis, Obesity and end of Life.
The SMCTM solution is deployed across multiple CCG’s and provider in the UK with over 10,000 patients benefiting from the system over the past 5 years. We have supported different operational and clinical pathways, including effective system deployment into patient homes and Care Home environments that can then enable pro-active and pre-emptive alerts to be raised with a Clinical care team.  Our technology and services have also been selected by a wide range of organisations including BT Health, Alere, Welch Allyn, MSD Commercial, Healthcare @Home to support new and existing service models in the field of telehealth.
 
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Mental Health: recovery, crisis and prevention / Long term conditions: a whole system, person-centred approach / Wellness and prevention of illness / Education, training and future workforce / Wealth creation / Clinical trials and evidence / Digital health / Innovation and adoption / Patient and medicines safety / Person centred care
Benefit to NHS:
Key deliverables achieved with SMCTM solution:
  • Facilitate early patient discharge and reduce bed days: Harrow CCG, 2014: achieved a 50% reduction in unplanned admissions and 63% bed day reduction to deliver an ROI of 159% and net savings of £3,444 per COPD and cardiac patients.
  • Improve prevention and early intervention:  Derbyshire Community Hospital, 2014: achieved a 68% reduction in unplanned admissions; 415 bed day reduction across 187 patients in a 6 month period with a net saving of c£100,000.
  • Improve service value and efficiency of service provider: Bristol CCG, 2013: within just 30days of the telehealth service starting the number of contacts reduced by 26% with an 18% reduction in face to face time and 40% reduction in telephone contacts
  • Sustain independent living and improve patient outcomes: Birmingham Community Health, 2014: Surveyed 312 patients with 86% of patients stating system helped them manage their condition; 84% more involved in their care; 90% happy to reduce the number of routine hospital visits.
     
Initial Review Rating
4.20 (1 ratings)
Benefit to WM population:
SMC offers multiple benefits for patients:
  • Personalised care modules: supports an individual's care needs using the most relevant questionnaires, vital signs and content.
  • Embedded educational content: on demand video aids training, behaviour change, understanding and the confidence for patients to self-manage their condition.
  • Sustains independent living: the use of relevant, integrated and familiar technology empowers patients to better understand and manage their conditions at home.
  • Easy to use and "out of the box": use fo familiar smartphones and tablets with wireless peripherals; audio and multi-lingual options.
  • Remote access and support software: touchscreeen enabled device support over the phone.
  • Video tele-consultation: remote "face to face" clinical consultation to aid better clinical intervention.
  • Text messaging: enable cost effective self-care.
  • Better patient outcomes: improves quality of life, reduces anxiety and increases confidence.
Current and planned activity: 
The SMC solution is deployed across multiple CCG’s and provider in the UK with over 10,000 patients benefiting from the system over the past 5 years. We have supported different operational and clinical pathways, including effective system deployment into patient homes and Care Home environments that can then enable pro-active and pre-emptive alerts to be raised with a Clinical care team.   Our technology and services have also been selected by a wide range of organisations including BT Health, Alere, Welch Allyn, MSD Commercial, Healthcare @Home to support new and existing service models in the field of telehealth.
We have long standing partnerships with Somerset CCG, Cornwall Foundation Trust Rotherham NHS Foundation Trust, and Dudley CCG and have been awarded innovator partnership on two Test Beds, one in Surrey and one in Manchester (with MSD Commercial.)

We support other conditions and pathways: Cystic Fibrosis, Falls and UTI, Spina Bifida children, LTC6 and E5QD quality of life.
Return on Investment (£ Value): 
N/A
Return on Investment (Timescale): 
N/A
Ease of scalability: 
Simple
Read more
Hide details
Elisabeth Barbosa 12/01/2017 - 17:57 Publish Login or Register to post comments
0
0
Votes
-99999
Innovation 'Elevator Pitch':
More people die of SUDEP (Sudden Unexpected Death in Epilepsy) than in house fires every year.
 
Every home has smoke detector, so why shouldn’t all epileptics have a device that alerts people close by so that they can provide assistance when needed?
Overview of Innovation:
Embrace is the world’s 1st system for seizure detection based on analysing multiple physiological data sensed at the wrist.



Should someone with Epilepsy experience an ‘unusual event’, such as a convulsive seizure, an alert will be sent via their smartphone to parents, friends or caregivers, summoning immediate help. Additionally, a caregiver can also wear a 'companion' Embrace. When the two Embraces are within range (e.g. in nearby rooms), the 'companion' Embrace worn by the caregivers will vibrate to alert them.

The Embrace watch has received awards for its design & innovative technology. The watch monitors Electrodermal Activity (EDA), also known as Galvanic Skin Response (GSR), which is autonomic data that is activated by regions deep in the brain involved in emotions such as fear, anxiety & excitement.
 
Embrace watch also functions as a sleep monitoring & activity tracking device.
 
What else do Embrace sensors monitor?
Embrace comes with an app called Mate. Mate combines events that are entered manually with events that are sensed by Embrace. Mate helps see how patterns of sleep, autonomic stress, skin temperature and physical activity may interact with seizure events. (NB: initial release of Mate app features rest and activity information, while features like autonomic stress monitoring, are still in development and will be added later). For example, if there are an increased number of absence seizures when stress levels have been high and sleep has been irregular, then these can be tracked to see if changing these patterns reduces the number of seizures.
 
Embrace and Alert app system for seizure detection is for investigational use only. The system is currently not clinically proven to detect seizures. Evidence of seizure characterization using the technology in Embrace has been gathered in a number of clinical trials since the initial discovery of skin conductance changes during a seizure was published in 2012. Empatica is currently conducting clinical trials to evaluate seizure detection of generalised tonic clonic seizures (GTCS) using the Embrace watch & Empatica Alert app.
 
The automatic physiological data logging provided by the Embrace system is valuable when someone experiences a seizure as they may not remember what has happened themselves. A diagnosis is often based on finding out what happened to the individual before, during and after a seizure.
 
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Wellness and prevention of illness / Wealth creation / Clinical trials and evidence / Digital health / Innovation and adoption / Patient and medicines safety / Person centred care
Benefit to NHS:
The number of people in the UK diagnosed with epilepsy has risen sharply in recent years. There are around 65 million people living with epilepsy in the world, with an estimated 600,000 people in the UK.
 
Every day in the UK, 87 people are diagnosed with epilepsy. Only 52% people with epilepsy in the UK are seizure-free.
 
During 2013, 1,187 people in the UK with epilepsy died earlier than expected (premature death). Some of these deaths could have been prevented. A clinical audit of epilepsy deaths in 2002 found that 64 per cent of adult deaths and over half of child deaths were possibly or probably avoidable.
 
Epilepsy is misdiagnosed in 20-30% of cases: most commonly, non-epileptic conditions are incorrectly diagnosed as epilepsy. Up to 40% of children referred to a tertiary clinic do not have epilepsy.  In 2004, the National Institute for Clinical Excellence (NICE) estimated the direct costs of epilepsy misdiagnosis (including inappropriate treatment, but not including individuals’ lost productivity from misdiagnosis) to be between £130m and £190m per year (NICE (2004) Epilepsy, second consultation, Appendix G).
 
Limiting the rate of misdiagnosis will help to reduce the risk of teratogenicity in wrongly diagnosed patients and will prevent patients wrongly diagnosed with epilepsy from facing, for example, unnecessary restrictions in employment and in other areas of life. Better diagnostic services are also likely to reduce any treatment gaps or inequalities, and, through encouraging independent living, improve the rate of employability for people with epilepsy. Finally, patients will have a greater choice of treatment options and a greater sense of empowerment
 
Epilepsy is an ambulatory-sensitive condition, meaning that better management in the community or primary care setting can effectively avoid unnecessary visits to the emergency department and non-elective hospital admissions.
 
Prevention of 15 admissions to hospital would Save the salary of a single epilepsy nurse
Estimate from National Audit of Seizure Management in Hospitals 2 (NASH2)
 
In 2009, there were 13 million prescription items of anti-epileptic drugs dispensed in the community in England, at a net ingredient cost of £300 million (NHS Information Centre Prescription Cost Analysis 2009. The net ingredient cost is the cost of the drug before discounts, not including any dispensing costs of fees).
Initial Review Rating
4.60 (1 ratings)
Benefit to WM population:
Epilepsy affects 54,000 people in the West Midlands (Source Birmingham City Council May 2016). The economic and social costs of managing this cohort is very significant.
 
Gaining control of one’s epilepsy not only saves direct health related costs in terms of fewer emergency or longer term hospital admissions, but also enables individuals with epilepsy to continue working and maintain their independence.
Current and planned activity: 
Current activity:
The Embrace device was only recently launched in the UK in November 2016. Currently clinical trials are taking place in the USA.
https://support.empatica.com/hc/en-us/sections/200817625-Seizure-Characterization-Clinical-Trial-monitoring-with-Embrace
 
We have taken orders from a number of Local Authority Assistive technology departments and are keen to engage further with the NHS.

Planned/future activity:
The published trial results cited above were from predicate devices. We need to collect more data using the Embrace and Alert app to complete the medical and FDA certification processes before we are able to make any claims regarding seizure detection performance of this system.
 
We are very keen to work more closely with any West Midlands network that provides support to people with Epilepsy or Autism.
 
What is the intellectual property status of your innovation?:
Patents Held by Empatica – further info available upon request.

The device is currently being fast tracked through FDA approval.

It also holds - Certifications:  CE Mark, FCC CFR 47 Part 15,  RoHS.
Return on Investment (£ Value): 
Very high
Return on Investment (Timescale): 
0-6 mon
Ease of scalability: 
Simple
Read more
Hide details
Ben Carter 19/12/2016 - 13:34 Publish Login or Register to post comments
0
0
Votes
-99999
Innovation 'Elevator Pitch':
A functional, digital, patient-centric, diabetes self-test system providing: self-care; patient-professional shared decisions; proactive interventions; complications prevention; data integration pan NHS provider; multi-faceted NHS costs savings.
Overview of Innovation:
awergq3wrg3w
Stage of Development:
Evaluation stage - Representative model or prototype system developed and can be effectively evaluated
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Advanced diagnostics, genomics and precision medicine / Wellness and prevention of illness / Education, training and future workforce / Wealth creation / Clinical trials and evidence / Digital health / Innovation and adoption / Patient and medicines safety / Person centred care
Benefit to NHS:
wefefgvw
Benefit to WM population:
f23ef2e
Current and planned activity: 
23rwefw
What is the intellectual property status of your innovation?:
fwergq3r5g
Return on Investment (£ Value): 
medium
Return on Investment (Timescale): 
2 years
Ease of scalability: 
Simple
Read more
Hide details
Baldev 31/10/2016 - 14:26 Archived Login or Register to post comments
0
0
Votes

Innovation 'Elevator Pitch':
Swifti is an app designed to address a gap in the mental health services.  It provides service users with a flexible, quick and convenient method of connecting with mental health practitioners.  
Overview of Innovation:
 
  • Specifically, the app has been designed to target individuals who may have been referred to the service, but struggle to access it due to issues such as  the debilitating nature of mental health or lengthy waiting lists. 
  • Through the app, service-users are able to book appointments in advance and cancel upcoming appointments. They can also be notified about their upcoming appointments.
  • Mental health practitioners are also able to advertise last-minute appointments that they have (e.g. up to two days prior to the appointment), which may have come about via cancellation with short notice. 
  • The aim of this is not only to make more efficient use of the practitioners’ time, but to also create a flexible appointment system for individuals who are unable to access the service initially due to being too psychiatrically unwell to attend (Killaspy, 2000), work schedules and ongoing disengagement.
  • In addition, users of the app will be able to engage in live message and video chats with practitioners if they are unable to physically attend their appointment. 
  • Moreover, if practitioners such as (Clinical Psychologists/Assistant Psychologists/CBT Therapists) have spare time to attribute to this facility, they can also go live outside of set appointment times in order to speak to various service-users who would like a brief chat at the time.  This should enhance the connection that the NHS mental health service has with their service-users and may prevent some individuals from falling through the gap when being referred for psychology. 
  • On the app there will also be the option for a swift feed which informs the app users of upcoming events which they may wish to attend and that latest information which is relevant to their healthcare.
  • Furthermore, self-help tools such as Mindfulness and Cognitive Behavioural Therapy (CBT) will also be accessible on the app.
  • NHS mental health staff members will also be able to access each individual’s case file via the app.
  • This app has not been designed to be abused and relied upon as a way of avoiding face-to-face contact with mental health practitioners.  Instead, it has been developed with a brief intervention in mind, when conventional methods fail.  The hope is that service-users may be able to utilise this facility for up to a few months before working their way up to face-to-face contact.  Long-term exceptional circumstances, such as work schedule related disengagement, may also be considered at the discretion of the practitioners.
Stage of Development:
Ideas stage - Early concept and ideas stage
WMAHSN priorities and themes addressed: 
Mental Health: recovery, crisis and prevention / Long term conditions: a whole system, person-centred approach / Wellness and prevention of illness / Wealth creation / Digital health / Innovation and adoption / Person centred care
Benefit to NHS:
Swifti aims to improve the efficiency of the mental health services by targeting service-users who do not thrive from conventional methods of communication.  The app will also increase savings for the NHS by utilising the time of mental health practitioners more efficiently and reducing the likelihood of missed appointments.  
Initial Review Rating
3.00 (1 ratings)
Benefit to WM population:
This app will create a flexible appointment system and an interactive medium for individuals who are unable to access the service, due to being too psychiatrically unwell to attend (Killaspy, 2000), work schedules and ongoing disengagement.  646,656 outpatient appointments were missed in 2011-2012 across the West Midlands region (BBC, 2012). The issue of missed appointments appears to be a growing problem, whilst disrupting the continuity of care for service-users and costing the NHS millions every year.
Current and planned activity: 
There are no other stakeholders and I have no current communications with the NHS regarding this app. I would appreciate some support and guidance with the development of the app and presenting the final product to NHS commissioners.
What is the intellectual property status of your innovation?:
I have written a business plan for the app which I have now copyrighted.
Return on Investment (£ Value): 
Very high
Return on Investment (Timescale): 
1 year
Ease of scalability: 
2
Read more
Hide details
Vanessa Gardner 28/10/2016 - 16:30 Sign Posted Login or Register to post comments
0
0
Votes

Innovation 'Elevator Pitch':
The Sound Doctor has over 250 high quality short educational films. Evaluations show they work by changing behaviours and improving outcomes to help people get the best out of life with long term conditions. 
Overview of Innovation:
The Sound Doctor is the leading provider of film and audio content for patients in the UK. Our content is thought to be unmatched in quality, range and production values and evaluations show it works by changing behaviours.and improving outcomes to help people get the best out of life with long term conditions.
 
Our films are endorsed by leading charities and adhere to NICE guidelines.
Conditions covered are COPD, Diabetes, back pain, dementia and weight management surgery.  A large series on heart conditions including cholesterol and hypertension, will be made shortly. 
There are over 250 films in our library so far and it is constantly growing.
We also create animations. We have a range of health and wellness short animations which are now being used in pharmacies and GP surgeries around the country. 
In addition, the team also devised and produce Health Today, a national radio programme for NHS England – nhs.uk/healthtodayradio
 
We have evidence that patients with diabetes, for example, have changed their attitudes towards diet and exercise as a result of watching our films. People with COPD are more confident about dealing with exacerbations at home. We also know that across all conditions they are considered a valuable part of people’s health care and improve patient experience.
 
The aims of The Sound Doctor, and there is evidence of this as well, are:
 
1. To reduce the number of avoidable admissions (and readmissions) to hospital
2. To reduce the need for face to face contact with consultants, physicians, nurses, physiotherapists and others (and to improve the quality of meetings which do take place)
3. To address the issue of co-morbidities by creating a multi-condition library
4. To improve medicines management and compliance with medications
5. To improve the quality of care for patients (and patient experience of their care)
6. To help people get the most out of life through effective self-management
   
About us:
The Sound Doctor was founded by Dominic Arkwright and Rosie Runciman and is a registered social enterprise.
Dominic worked as a reporter at the BBC for more than 20 years, mostly on Radio 4 's Today Programme as well as Newsnight and PM. He also presented discussion programme 'Off the Page' and 'The Call' on Radio 4.
Rosie Runciman also worked at the BBC for more than 20 years on Radio 4's Today programme, Newsnight, Radio 5 Live and at The World Service. She was Editor of Newshour and Assistant Editor at Five Live.
 
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Wellness and prevention of illness / Education, training and future workforce / Wealth creation / Digital health / Innovation and adoption / Patient and medicines safety / Person centred care
Benefit to NHS:
  • For clinicians 
    • Complements and supports sessions
    • Sessions more focused and efficient to achieve better health outcomes
    • Reduces appointments, admissions and DNAs
  • For providers 
    • More efficient caseloads, better outcomes for patients, reduced waiting lists
    • Money saved through reduced numbers of GP appointments, hospital admissions and DNAs
Return On Investment (GPs)
Cost of TSD per patient per annum = £5.00
 
Average number of GP visits pre TSD = 3.7 appointments Average number of GP visits post TSD = 0.42 appointments
 
3 fewer appointments per TSD user x payment for each appointment of
£23.50 (NHS tariffs) = £70.50 per patient; an ROI of 1:14
 
Average number of GP DNAs pre TSD = 2.5 appointments Average number of GP DNAs post TSD = 0.5 appointments
 
2 fewer DNAs per TSD user x cost of each DNA of £36 (Kings Fund) = £72 per patient; an ROI of 1:14
Initial Review Rating
3.80 (1 ratings)
Benefit to WM population:
Benefits for patients
  
  • Empowers and encourages people’s engagement with their condition
  
  • Improves medicines adherence
  
  • Improves overall quality of care
  
  • Improves people’s experience of and satisafaction with their care
Current and planned activity: 
Who’s using The Sound Doctor
•  CCGs 
  • Barnsley, Gloucestershire, West Leicester, Wirral, Newcastle, Central London Community Health Trust
  
  • Hospital Trusts 
    • Guy’s and Tommy’s NHS Trust
    • Liverpool Heart and Chest Hospital
  
  • Other 
    • Philips Healthcare
    • All South London pharmacies
    • Jhoots Pharmacies
    • NAPC Practice Innovation Network
    •  
 
What is the intellectual property status of your innovation?:
We own the IP on all our content
Return on Investment (£ Value): 
Very high
Return on Investment (Timescale): 
0-6 mon
Ease of scalability: 
Simple
Read more
Hide details
Dominic Arkwright 26/09/2016 - 16:02 Publish 1 comment
5
1
Votes
-99999
Innovation 'Elevator Pitch':
BVI technology is an innovative and easy to use, mHealth service to determine the percentage and distribution of visceral fat using a mobile device (tablet) or a smart phone. 
Overview of Innovation:
The Body Volume Indicator (BVI) is a new measurement for healthcare and obesity. After eight years of successful and innovative validation from scientific collaborators around the world, BVI is now undergoing final testing prior to a full launch later in 2017.

Using 3D technology, BVI calculates risk factors associated with a person's body shape, by measuring weight and body fat distribution, with particular focus on the abdomen; the area associated with the greatest risk.

BVI is designed to be a long-term addition to the Body Mass Index (BMI); the current recognised standard for measurement of obesity. The intention is for the Body Volume Indicator to become a Body Volume Index by 2020, by which time sufficient data will have been collected globally. Using smartphone technology, BVI data can now be collected anywhere with web or internet access.

Body Volume, as an indicator of health, offers a potential long-term solution as a measure of individual health risk. 

BVI was developed in the West Midlands and collaborators have included Heartlands Hospital, Aston University, Mayo Clinic and the Medical Research Council. The application was patented in the US in 2012 and throughout Europe in 2015.


 
Current Status
In 2012 Select Research obtained exclusive use of the largest and most comprehensive collection of Body Composition Data (BCD) of visceral fat data from MRI scans in the world. This has been used to develop an App which will be used to scan/photograph lightly clothed patients and then comparing their BCD database to predict their body fat and visceral fat.
 
Further research and development is being undertaken with our current BVI (Body Volume Index) tool, to provide additional evidence and to validate the efficacy, and appropriateness of this BVI application in real-life environments. Through a ‘real-life’ project work with WMAHSN will provide clinical validation for the underpinning methodology, thus making potential users (Clinicians, patients & public) aware of the benefits (social and economic) of utilising the service.
 
Thus our current BVI application is to be incorporated into the existing patient pathways currently used by Health Exchange Health Trainers in the West Midlands.
 
NB: The application has been patented in the US in 2012 and throughout Europe in 2015 and covers all measurements of part body volume for healthcare from a 3D scan. Body fat is a part volume of the human body.

Please assist us with our 5 min Survey http://BVISurvey.SSIsurveys.com​ 
Stage of Development:
Evaluation stage - Representative model or prototype system developed and can be effectively evaluated
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Advanced diagnostics, genomics and precision medicine / Wellness and prevention of illness / Wealth creation / Clinical trials and evidence / Digital health / Innovation and adoption / Person centred care
Benefit to NHS:
Visceral fat is body fat stored within the abdominal cavity around a number of important internal organs such as the liver, pancreas, and intestines often referred to as 'active fat'. This type of fat plays a potentially dangerous role in affecting how our hormones function.

Higher amounts of visceral fat are associated with increased risks of a number of health problems.  NHS healthcare costs attributed to obesity are £5.1b p.a. and set to rise by £7.1b by 2030; The cost to the UK economy is £27b p.a. Benefits through effective intervention based on accurate visceral body fat determinations are complex but undoubtedly would lead to a reduction in the burden of obesity (diabetes, heart disease, stroke, and certain cancers), by a reduction in years lost to premature mortality and disability (DALY). NICE suggests reducing obesity of 1% would save the “NHS and local authorities around £97 million per year.” Diabetes costs the NHS over £1.5m an hour or 10% of the NHS budget for England and Wales. 

The lifetime benefits of weight loss - direct £297 and indirect £2068 estimates based on 50% compliance and 25% success.  A saving to the NHS of between £1.2m and £6.9m, and the economy of between £135m and £1620m.

Select’s BVI tool App predicts the early identification body and visceral fat & estimates via a quick, simple and non-invasive scan which provides an insight and benchmark for clinicians and their patients; just by taking two photographs of a patient. 

Therefore BVI significantly contributes to the monitoring, intervention and control processes for clinicians and other health professional to apply, so that they can tackle and halt the potential for escalation into Diabetes and CHD etc.


Particular value for patients will be that they can monitor their own progress and to improvement at home. Through recognition of the scale of their own obesity and particularly any high levels of visceral fat. The early identification of visceral fat, through this simple, quick and accurate method of measuring obesity will thus take a large step towards achieving considerable saving to the NHS and the UK economy.

The proposal for delivery of BVI is under discussion with BVI data (including BMI, Waist Circumference, and Waist to Hip Ratio automatically) stored for tracking purposes on patient records via the N3 spine. Automatic data collection through BVI of current methods saves time, money and provides new informative data on body composition for future research.
Online Discussion Rating
5.50 (2 ratings)
Initial Review Rating
5.00 (1 ratings)
Benefit to WM population:
Clinical Outcomes & Economic
In the West Midlands 65.7 per cent of people are carrying excess weight, along with 65.6 per cent of people in the East Midlands. Obesity costs the UK economy exceed £3 billion per year. In Birmingham, over 25% of the population are obese - the third highest rate in the UK. The high prevalence of obesity in adults within England show that national averages of over 40% of males overweight and more than 20% obese in the 16-75 year age range, while in women the averages are lower for the overweight classification but higher for obesity.
 
Nationally GPs make 97,000 annual referrals to weight watching programmes (WWP) and costs will reach £15.6m p.a. in 2017. A saving of £48.5 per patient might be made using the BVI App. With as low as 10% uptake, £0.5m could be saved, rising to £2.8m with a 60% uptake. Better management of weight issues with patients will have significant cost savings within the West Midlands.
 
This tool will support early detection of visceral fat and therefore allow a much more preventative and timely approach to supporting West Midlands Patients to make positive lifestyle change.
 
Environmental
The BVI App offers considerable environmental benefits in reducing the number of visits (road trips) to a surgery and specialist clinics. It will also allow people within remote and rural locations to engage in such activities.
 
Research
Additional R&D is being undertaken with the WMAHSN, to further ‘validate’ the efficacy, appropriateness and validity of the BVI application in real-life environments using the BVI App, which is being incorporated into the existing patient pathways.
 
Commercially
The adoption of this technology within the West Midlands and UK will also allow our company to grow and develop, not only with increasing its functions and capabilities but also in marketing this to a worldwide healthcare organisations and individuals as obesity is a major developed countries epidemic. 
 
There is also interest from other commercial organisations involved in weight management and associated healthcare which will further extent this products role and integration with people taking charge of their well being.

Trials
The BVI tool will be tested in 3 locations in the West Midlands with patients and GP Practices in Birmingham, Dudley and Solihull. Analysis of weight loss achieved over a period will be monitored.

Please assist us with our 5 min Survey http://BVISurvey.SSIsurveys.com​ 
Current and planned activity: 
Current BVI application is undergoing R&D and incorporation into existing patient pathways within the West Midlands via;
  • Patient Engagement - Face to face consultation, scanning of approximately 1000+ patients
  • Clinical Benefits - Analysis and monitoring of weight loss achieved over a defined period. Developing delivery protocols
  • Dissemination - Facilitation of BVI tool awareness raising sessions with Key Public Health and NHS Management, Clinical Teams and frontline staff
  • Training - BVI tool training to specialist clinical teams (Primary & Acute), ensuring correct use of the tool and providing feedback for use with patients
  • Data analysis – Verification/validation of App algorithms
  • Data gathering - Provision of clinically requested data – Core data profiling to gauge health outcomes and patient benefits. Establishing minimum data requirements
Required
  • Evaluation & Trials - Seeking trial interests
  • Adoption – Looking for discussions with CCG’s, Healthcare and Council Health Prevention teams   
What is the intellectual property status of your innovation?:
BVI has both BVI Patents and Trademarks approved.
Return on Investment (£ Value): 
Very high
Return on Investment (Timescale): 
6-12 mon
Ease of scalability: 
Simple
Regional Scalability:
We have not as yet implemented at scale within the WM region or elsewhere. The BVI product will be launched in the US market in March 2017 and Select Research Ltd are currently in discussions with Health Exchange and NHS Heartlands Hospital (who are collaborators on BVI development) for a possible follow on wider trial across the region for 2017.
Measures:
When the BVI app has been fully completed in terms of it’s scalability for widespread use, the trial results have been published and the launch takes place in April 2017, the success criteria will be determined by the number of users and the take up when the product is available and being used by customers.
 
Development is currently ongoing with scaling of the technical infrastructure for release on all accepted and recognised technical platforms (e.g. Google Play. App Store) in late April 2017. The success criteria will then become easily measurable by virtue of the volume of downloads achieved after launch.
Adoption target:
These will be dependent upon the outcome of the discussions with NHS Heartlands Hospital and Health Exchange as to a future extended trial.
Read more
Hide details
Richard Barnes 16/08/2016 - 13:59 Approved Login or Register to post comments
0
0
Votes

Innovation 'Elevator Pitch':

The NHS often does NOT know a patient’s wishes on treatment, their preferences or instructions. In a health emergency or mental crisis this information is vital.. MyDirectives gives everyone the chance to record their wishes in advance of a crisis.

Overview of Innovation:

MyDirectives.com and MyDirectives mobile gives every individual the opportunity to record their wishes for free. The service uses digitally delivered structured forms, video and audio messages to create high quality documents that health professionals trust to make best interest decisions. The service empowers individuals, allowing them to share their wishes with a close network of people (‘agents’) they trust to support them in a crisis or if they are unable to speak for themselves.  These ‘agents’ are sent instructional packs & urged to discuss preferences with the individuals concerned. MyDirectives then works with local health economies to integrate the person’s wishes & personal choices with primary, secondary and local authority databases & electronic health records so they can be confident their wishes & ‘digital voice’ will always be accessible & heard.
 
For health professionals this means they can be confident they are looking at the most up to date views of their patients, know who can speak for the patient & what their treatment choices & objectives are. This approach is both ‘human’ & from an innovation perspective, highly disruptive. It leads to faster, more appropriate & sensitive care decision making & can be easily scaled through MyDirectives' API to the whole care & health community.
 
The benefits of this pro-active approach are significant cash releasing savings that can be evidenced. An indication of how much this approach might save a health economy is a bill currently going though both houses of the US Congress that proposes to give every US citizen on Medicaid and Medicare £75 in return for creating a digital emergency, critical and advance care plan. MyDirectives has been live for four years and is used by individuals in 34 countries & is now looking for its first healthcare partner in the UK. 

We want a healthcare partner who can work with us to establish a UK integration network with GP suppliers, summary care record and organ donor lists and an adoption strategy using GP suppliers, secondary care providers, E-referrals, organ donor register and NHS Choices. We believe we can create a national system of adoption and retrieval using the NHS’ existing infrastructure. The end result will be a cost effective mechanism for recording and retrieving a patient's ‘voice’.

MyDirectives is the only company providing an integrated all digital solution to these issues.
 
See https://mydirectives for further details.

Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Mental Health: recovery, crisis and prevention / Long term conditions: a whole system, person-centred approach / Wellness and prevention of illness / Wealth creation / Digital health / Innovation and adoption / Person centred care
Benefit to NHS:

ADVault has created an economic model for England that shows for every £1 spent on MyDirectives a health authority would save between £1.77 to £9.33 within five years. The variation depends on which NHS England figures you apply to the model. Please see attached five case national economic model created for HM Treasury for full details. The models are based on targeting the entire adult population of a health economy and capturing 25% of all deaths.

If the NHS were to set a 50% adoption level and the capture of 25% of all deaths within five years as achievable targets, it could expect to generate net savings of between £64,916,693 to £702,791,693 per annum by the end of year five. A city such as Birmingham could therefore expect to save c£6m a year.

These cost savings can be realised as individuals express in their Emergency, Critical and Advance Care Plans (ECACP) their preferences, wishes and goals for treatment and care that permit the NHS to intervene more appropriately and less intensively.  As a result, ECACPs lead to fewer people dying in hospital, reduced admissions, achieve shorter hospital stays, reduced unnecessary ambulance journeys, fewer ‘heroic’ treatment measures and fewer incidences of distressing and unwanted life-sustaining treatments.
 
With an ECACP there is also compelling evidence that carers return to work sooner following family health crises and bereavements and experience fewer subsequent mental health issues, as the end of life events are managed more sympathetically.  Anecdotal evidence suggests even more significant savings following unexpected accidents and trauma where an ECACP is in place.

MyDirectives is supported by the National Council for Palliative Care (CEO Claire Henry); Baroness Finlay, the Chair of the National Mental Capacity Forum and Professor Bee Wee, the National Director for End of Life Care.

We are currently looking for our first NHS partner.

Initial Review Rating
4.40 (2 ratings)
Benefit to WM population:

In addition to the benefits described in the previous section, we are looking for a regional partner such as a GP group, Trust or STP to showcase and then spread this innovation across the wider NHS. We would be comfortable to enter into a commercial arrangement to facilitate this partnership.
 
If a suitable regional partner can be identified, we would consider locating our UK business Headquarters in the West Midlands.
 
Given the health economic forecast described previously and the predictive benefits model for saving to NHS England a city such as Birmingham could expect to save approximately £6m a year.

Current and planned activity: 

ADVault, creators of MyDirectives, is looking for its first UK integration partner. In the USA our integration business is now operating successfully in 10 US States. In addition, we are also in discussions with the Australian Federal government.

We are seeking a regional partner such as a GP group, Trust or STP to showcase the product and then to spread this innovation across the wider NHS community.
 
We would be comfortable to enter into a commercial arrangement to facilitate this partnership
 
Should suitable regional partners be found, we would consider locating our UK business headquarters within the West Midlands.

What is the intellectual property status of your innovation?:

All the intellectual property is owned by ADVault Inc

Return on Investment (£ Value): 
Very high
Return on Investment (Timescale): 
3 years +
Ease of scalability: 
Simple
Regional Scalability:

MyDirectives can be scaled regionally or nationally. We generate better viral effects when we approach hundreds of thousands of people. This also "normalises" the process of recording you preferences, values and goals making success more likely. 

Measures:

Outcomes will be measured digitally based on volume of take up, retrieval and completion. We would also bring in researchers to look at impact on ambulance journeys, 111 decision making, medical crisis decision making, length of stay in hospital, organ donation rescind rate and deaths in normal place of residence.

Adoption target:

ADVault would seek to have 50% of a population signed up within five years. One of the consequence of this penetration would be that approx 25% of people in a community are likely to have one in place prior to a medical crisis.

Read more
Hide details
Jonathon Carr-Brown 27/07/2016 - 17:24 Detailed Submission Login or Register to post comments
0
0
Votes
-99999

Active Campaigns